351 306

Cited 6 times in

Effect of High-Dose Statin Loading on Biomarkers Related to Inflammation and Renal Injury in Patients Hospitalized With Acute Heart Failure

 Jaewon Oh  ;  Seok-Min Kang  ;  Namki Hong  ;  Jong-Chan Youn  ;  Sungha Park  ;  Sang-Hak Lee  ;  Donghoon Choi 
 CIRCULATION JOURNAL, Vol.78(10) : 2447-2454, 2014 
Journal Title
Issue Date
Acute Kidney Injury*/blood ; Acute Kidney Injury*/mortality ; Administration, Oral ; Aged ; Aged, 80 and over ; Atorvastatin Calcium ; Biomarkers/blood ; Female ; Heart Failure*/blood ; Heart Failure*/complications ; Heart Failure*/drug therapy ; Heart Failure*/mortality ; Heptanoic Acids/administration & dosage* ; Heptanoic Acids/adverse effects ; Hospital Mortality ; Hospitalization* ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage* ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Male ; Middle Aged ; Natriuretic Peptide, Brain/blood* ; Peptide Fragments/blood* ; Pilot Projects ; Prospective Studies ; Pyrroles/administration & dosage* ; Pyrroles/adverse effects
Acute decompensated heart failure ; Biomarkers ; Statins
Background:High-dose statin loading is known to reduce periprocedural myocardial infarction and contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. However, the clinical role of high-dose statin loading in patients with acute heart failure (AHF) remains unknown.Methods and Results:In a prospective, single-center, randomized, controlled, open-label pilot study, patients hospitalized with AHF were randomly assigned to receive oral high-dose atorvastatin loading (80 mg for 3 days, followed by 10 mg/day until discharge) or no statin therapy, on top of optimal HF treatment. The primary outcome measures were changes to the level of biomarkers related to inflammation and renal injury from admission to hospital day 4. No significant changes in the levels of NT-proBNP (−2,627±4,956 vs. −2,981±6,951 pg/ml, P=0.845), hsCRP (−6.1±16.4 vs. −2.1±16.2 mg/L, P=0.105), cystatin C (0.002±0.185 vs. 0.009±0.216 mg/L, P=0.904), ACR (−886.3±1,984.9 vs. −165.6±825.2 mg/day, P=0.124) were observed in either group. In-hospital mortality (4.3% vs. 3.8%, P>0.999) and all-cause mortality at 90 days (4.3% vs. 3.8%, P>0.999) were not significantly different between groups.Conclusions:This pilot study showed that oral high-dose atorvastatin loading may be used safely in patients with AHF, but is not effective in reducing the levels of circulating biomarkers related to inflammation and renal injury during hospitalization.
Files in This Item:
T201403565.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Min(강석민) ORCID logo https://orcid.org/0000-0001-9856-9227
Park, Sung Ha(박성하) ORCID logo https://orcid.org/0000-0001-5362-478X
Oh, Jae Won(오재원) ORCID logo https://orcid.org/0000-0002-4585-1488
Youn, Jong Chan(윤종찬)
Lee, Sang Hak(이상학) ORCID logo https://orcid.org/0000-0002-4535-3745
Choi, Dong Hoon(최동훈) ORCID logo https://orcid.org/0000-0002-2009-9760
Hong, Nam Ki(홍남기) ORCID logo https://orcid.org/0000-0002-8246-1956
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.